COLLEGIUM PHARMACEUTICAL, INC
No SEC Form 4 filings for $COLL in the last 30 days.
See all $COLL insider activity →Corcept (CORT) beat estimates and raised guidance, with its stock up 23.2%. Zoetis (ZTS) reported flat revenue, missing expectations, and its stock fell 4.2%. Collegium Pharmaceutical (COLL) saw a 6.3% revenue increase but missed guidance, with its stock down 36.7%. Pfizer (PFE) reported a 2.6% revenue increase, beating expectations, and its stock rose 14.8%.
Collegium Pharmaceutical (COLL) reported Q2 2026 results on an earnings call. Total net product revenue was $199.9M (+6% YoY). Jornay PM revenue rose to $46.1M (+41%) with 30,000+ prescribers. Azstarys revenue was $12.9M post-May acquisition. 2026 guidance: product revenue $825M-$855M; adjusted EBITDA $445M-$470M; adjusted EPS $1.92. Risks cited include authorized-generic pricing impacts.
Collegium Pharmaceutical shares rose about 3% in pre-open trading after the company announced a $50 million Accelerated Share Repurchase with Jefferies LLC. Collegium will pay $50 million upfront and receive about 1.56 million shares initially, under a $150 million buyback program authorized in July 2025. The firm reported Q2 net revenues near $199.9 million and reaffirmed 2026 guidance of $805–$825 million.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning COLL (COLLEGIUM PHARMACEUTICAL, INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent COLL coverage spans earnings, corporate actions and financial news.
Recap of already‑public earnings; limited trading relevance.
Guidance update shifts the balance between ADHD growth (Jornay PM, Azstarys) and pain franchise headwinds (Nucynta authorized generic pricing), affecting near-term valuation and risk premium.
The ASR tranche is a near-term capital return catalyst that can support the stock into the open, while reaffirmed 2026 guidance reduces downside risk.
The ASR provides a near-term reduction in share count and signals confidence in the ADHD and pain franchises, likely supporting sentiment.
Guidance cut and pain-portfolio pressure are the dominant drivers, likely keeping downside pressure until investors see stabilization in revenue durability.
AlphAI scores every news story that mentions COLL with an AI model for sentiment and relevance, and aggregates insider trades from COLLEGIUM PHARMACEUTICAL, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Corcept (CORT) beat estimates and raised guidance, with its stock up 23.2%. Zoetis (ZTS) reported flat revenue, missing expectations, and its stock fell 4.2%. Collegium Pharmaceutical (COLL) saw a 6.3% revenue increase but missed guidance, with its stock down 36.7%. Pfizer (PFE) reported a 2.6% revenue increase, beating expectations, and its stock rose 14.8%.
3 min readCollegium Pharmaceutical (COLL) reported Q2 2026 results on an earnings call. Total net product revenue was $199.9M (+6% YoY). Jornay PM revenue rose to $46.1M (+41%) with 30,000+ prescribers. Azstarys revenue was $12.9M post-May acquisition. 2026 guidance: product revenue $825M-$855M; adjusted EBITDA $445M-$470M; adjusted EPS $1.92. Risks cited include authorized-generic pricing impacts.
8 min readCollegium Pharmaceutical shares rose about 3% in pre-open trading after the company announced a $50 million Accelerated Share Repurchase with Jefferies LLC. Collegium will pay $50 million upfront and receive about 1.56 million shares initially, under a $150 million buyback program authorized in July 2025. The firm reported Q2 net revenues near $199.9 million and reaffirmed 2026 guidance of $805–$825 million.
4 min readCollegium Pharmaceutical (NASDAQ:COLL) shares rose about 4% premarket after it announced a $50 million accelerated share repurchase with Jefferies LLC. The ASR is part of a $150 million buyback authorized in July 2025, leaving $100 million after completion. Collegium will pay $50 million and initially receive 1,556,420 shares based on a $25.70 Aug. 12, 2026 close; final settlement expected by Q4 2026.
2 min readCollegium Pharmaceutical shares fell about 13% in pre-open trading after it reported Q2 2026 results and cut full-year revenue guidance. Net revenues were $199.9M, up 6.3% but below analysts’ ~$201.2M-$201.4M. Adjusted EPS was $1.92 and adjusted EBITDA $113.8M. The pain portfolio faced generic competition, while JORNAY PM rose 41% to $46.1M and AZSTARYS added $12.9M.
4 min readCollegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2026 revenue of $199.9 million, up 6.3% year on year but below analyst estimates. Full-year revenue guidance of $840 million midpoint was 3.4% under consensus. Non-GAAP EPS was $1.92, up from $1.68 and 8.8% above estimates. The stock fell 6.6% to $33.37.
3 min readCOLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress – Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Y
7 min readCollegium Pharmaceutical (COLL) will report earnings Thursday before market open. The company previously posted $193.5M revenue, up 8.9% year over year, and beat EPS estimates but missed full-year revenue guidance. For the upcoming quarter, analysts expect revenue growth of about 7% y/y. COLL shares are below its average $53.60 analyst price target.
3 min readCollegium Pharmaceutical (NASDAQ:COLL) reported Q1 2026 results on May 7, with revenue up 9% YoY to $193.5 million, beating the Street’s $187.4 million estimate. Adjusted EPS rose to $1.76 from $1.49 and topped expectations of $1.63. The company cited strong ADHD franchise growth, including Jornay PM sales up 36% YoY, and expects Jornay PM revenue of $190–$200 million in 2026. Collegium also plans to expand its ADHD portfolio via Azstarys acquisition, expecting it to add over $50 million to H2 2
5 min readCollegium Pharmaceutical (COLL) director Donovan Michael Glancy has filed an initial Form 3, indicating his start as a reporting person for the company. This filing discloses his initial ownership of Collegium Pharmaceutical securities but does not report any transactions or derivative positions. A Form 3 is a mandatory SEC filing for new insiders, establishing a baseline for their holdings.
1 min read
